Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans sodium crocetinate - Diffusion Pharmaceuticals

Drug Profile

Trans sodium crocetinate - Diffusion Pharmaceuticals

Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpd

Latest Information Update: 09 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Office of Naval Research; University of Virginia
  • Developer Diffusion Pharmaceuticals; University of Virginia
  • Class Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Stroke
  • Phase I Brain metastases; Pancreatic cancer
  • Research Adult respiratory distress syndrome
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 07 Jul 2020 Diffusion Pharmaceuticals files an IND application for a phase I/IIb trial with the US FDA for Adult respiratory distress syndrome and Hypoxaemia
  • 07 Jul 2020 Diffusion Pharmaceuticals plans a phase I/IIb trial in Adult respiratory distress syndrome and Hypoxaemia (associated with COVID-2019) in Romania and USA in July 2020
  • 11 Jun 2020 Diffusion Pharmaceuticals plans to submit an IND application with the US FDA for a clinical trial in Adult respiratory distress syndrome associated with COVID-2019 infections in June 2020, with expected accelerated response
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top